UK Court Ruling Ends Novartis/Bayer Crusade Against Avastin In AMD
Off-Label Use Does Not Undermine Licensing System
Executive Summary
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.